Compare BHVN & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHVN | TRIN |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2021 |
| Metric | BHVN | TRIN |
|---|---|---|
| Price | $10.54 | $15.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $29.79 | $16.00 |
| AVG Volume (30 Days) | ★ 4.4M | 752.1K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 13.35% |
| EPS Growth | N/A | ★ 25.79 |
| EPS | N/A | ★ 2.17 |
| Revenue | N/A | ★ $268,271,000.00 |
| Revenue This Year | N/A | $29.07 |
| Revenue Next Year | $2,219.74 | $13.52 |
| P/E Ratio | ★ N/A | $7.05 |
| Revenue Growth | N/A | ★ 30.76 |
| 52 Week Low | $7.48 | $12.50 |
| 52 Week High | $45.87 | $16.82 |
| Indicator | BHVN | TRIN |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 62.86 |
| Support Level | $8.29 | $14.47 |
| Resistance Level | $10.18 | $14.92 |
| Average True Range (ATR) | 0.76 | 0.24 |
| MACD | 0.34 | 0.08 |
| Stochastic Oscillator | 90.59 | 99.05 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.